Featuring perspectives from Dr Bradley J Monk, Dr David M O’Malley, Ms Kathryn M Schlenker and Ms Jaclyn Shaver, moderated by Dr O’Malley, including the following topics:

• Introduction (00:00)
• Overview of Ovarian Cancer (OC) (2:12)
• Role of PARP Inhibitors in Advanced OC (4:56)
• Current and Potential Future Role of Mirvetuximab Soravtansine in OC (28:45)
• Role of Relacorilant in Advanced OC (57:08)
• Utility of Immune Checkpoint Inhibition in Advanced OC (1:14:12)

NCPD information and select publications

Featuring perspectives from Dr Floor J Backes, Dr Brian M Slomovitz and Dr Shannon N Westin, moderated by Dr Westin, including the following topics:

• Introduction (00:00)
• Current Up-Front Chemoimmunotherapeutic Approaches for Advanced Endometrial Cancer (EC) — Dr Backes (1:50)
• Current and Future Role of Anti-PD-1/PD-L1 Antibodies in Combination with Systemic Therapies Beyond Chemotherapy for Advanced EC — Dr Westin (33:15)
• Promising Agents Under Investigation for EC — Dr Slomovitz (1:01:41)

CME information and select publications

Featuring perspectives from Dr Ramez N Eskander, Dr Ursula Matulonis, Dr Kathleen N Moore, Dr Alexander B Olawaiye and Dr David M O'Malley, moderated by Dr Moore, including the following topics:

• Introduction (00:00)
• Current Role of PARP Inhibitors in the Management of Advanced Ovarian Cancer (OC) — Prof Eskander (2:40)
• Strategies Targeting Folate Receptor Alpha in Advanced OC — Dr Matulonis (27:41)
• Other Approved and Promising Investigational Antibody-Drug Conjugates for Advanced OC — Dr Moore (52:12)
• Other Novel Agents and Strategies for Advanced OC — Dr O'Malley (1:14:35)
• Diagnosis and Management of Adverse Events Associated with Common Therapies for Advanced OC — Dr Olawaiye (1:39:39)

CME information and select publications

Featuring perspectives from Dr Floor J Backes, Dr Matthew A Powell and Dr Ritu Salani, moderated by Dr Salani, including the following topics:

• Case: A woman in her late 60s presents with mismatch repair-deficient metastatic endometrial cancer(00:00)
• Perspectives on neoadjuvant immunotherapy for microsatellite instability-high endometrial cancer (06:25)

CME information and select publications

Featuring perspectives from Dr Floor J Backes, Dr Matthew A Powell and Dr Ritu Salani, moderated by Dr Salani, including the following topics:

• Case: A woman in her late 70s with de novo metastatic mismatch repair-proficient metastatic endometrioid endometrial cancer (00:00)
• Molecular analyses in the assessment and management of endometrial cancer (07:33)

CME information and select publications

Featuring an interview with Dr Floor J Backes, including the following topics:

• Overview of the treatment landscape of endometrial cancer (00:00)
• Immunotherapy for advanced endometrial cancer (03:58)
• Contraindications for immunotherapy (18:15)
• PARP inhibitors for endometrial cancer (20:12)
• Management of localized endometrial cancer (28:23)
• Novel strategies under investigation for endometrial cancer (42:27)

CME information and select publications

Featuring perspectives from Ms Courtney Arn, Ms Jamie Carroll, Dr Edward B Garon, Dr Heather McArthur and Dr Kathleen N Moore, moderated by Dr Moore, including the following topics:

• Introduction (0:00)
• Overview of Antibody-Drug Conjugates (ADCs) (2:07)
• Current and Future Role of HER2-Targeted ADCs for Breast Cancer (6:23)
• Currently Available ADCs for Gynecologic Cancer Management (26:37)
• Currently Available ADCs for Lung Cancer Management (44:07)
• Current and Future Role of TROP2-Targeted ADCs for Metastatic Breast Cancer (56:55)
• Other ADCs That May Soon Reach the Clinic for Advanced Gynecologic Cancers (1:15:07)
• Promising Investigational Strategies Employing ADCs for Lung Cancer (1:25:01)

NCPD information and select publications

Featuring perspectives from Dr Dana M Chase, Ms Sarah Karpen, Dr J Alejandro Rauh-Hain and Ms Jaclyn Shaver, moderated by Dr Chase, including the following topics:

• Introduction: Biology of Endometrial Cancer (EC) (0:00)
• First-Line Therapy for Advanced or Recurrent EC (14:15)
• Potential Benefits of PARP Inhibition Combined with Immunotherapy in Advanced EC (35:13)
• Role of Lenvatinib/Pembrolizumab in the Management of Progressive Advanced EC (57:48)
• Other Nursing Considerations in the Care of Patients with Advanced EC (1:17:28)

NCPD information and select publications